Nemucore Medical Innovations, Inc to Open Nanomedicine GMP Manufacturing and Development Facility in Worcester, Massachusetts
Nemucore Medical Innovations, Inc. (NMI) recently signed a lease with the Massachusetts Biomedical Initiatives (MBI) for research space in Worcester, Massachusetts where development of life-saving nanomedicines for the treatment of drug resistant can
Online, November 30, 2010 (Newswire.com) - Nemucore Medical Innovations, Inc. (NMI), dedicated to the development and commercialization of life-saving nanomedicines for the treatment of drug resistant cancers, recently signed a lease with the Massachusetts Biomedical Initiatives (MBI) for space in Worcester, Massachusetts. The company will use the facility to conduct experimental research to scale-up for commercial production promising nanopharmaceuticals developed with research teams participating in Northeastern University's Center of Cancer Nanotechnology Excellence (CCNE), and by other collaborators and partners. The MBI facility allows NMI to further its research until it moves into larger space in Worcester that will support a significant enhancement of nanomedicine cGMP manufacturing and research space for additional employees.
"This new laboratory and the future cGMP facility represent critical components of our strategy to facilitate the development of a quality system to manufacture nanomedicine products in compliance with FDA guidelines and speed the translation from the laboratory to clinical investigation. We are committed to growing Nemucore in Worcester, and contributing to the creation of the biotechnology workforce in the region" said Dr. Tim Coleman, NMI President and CEO.
Kevin O'Sullivan, President and CEO of MBI, stated "We are pleased to have Nemucore Medical Innovations join the growing tenant list in the MBI life science incubator facilities, and have been impressed by Nemucore's commitment to growth in the Worcester region, and participation in the growth and expansion of biotechnology in Massachusetts."